MIL62 Plus Lenalidomide for Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (Follicular Lymphoma and Marginal Zone Lymphoma)
Condition:   Follicular Lymphoma and Marginal Zone Lymphoma Intervention:   Drug: Recombinant Humanized Monoclonal Antibody MIL62 Injection, lenalinomide Sponsor:   Beijing Mabworks Biotech Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 1, 2019 Category: Research Source Type: clinical trials

MIL62 Plus Lenalidomide for Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (FL and MZL)
Condition:   Follicular Lymphoma and Marginal Zone Lymphoma Intervention:   Drug: Recombinant Humanized Monoclonal Antibody MIL62 Injection Sponsor:   Beijing Mabworks Biotech Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 1, 2019 Category: Research Source Type: clinical trials

MIL62 Plus Lenalidomide for Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (FL and MZL)
Condition:   Follicular Lymphoma and Marginal Zone Lymphoma Interventions:   Drug: Recombinant Humanized Monoclonal Antibody MIL62 Injection;   Drug: Lenalidomide Sponsor:   Beijing Mabworks Biotech Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 1, 2019 Category: Research Source Type: clinical trials

Acalabrutinib With Rituximab and Lenalidomide in Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Condition:   Non-hodgkin Lymphoma,B Cell Intervention:   Drug: Acalabrutinib Sponsor:   Seoul National University Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 18, 2019 Category: Research Source Type: clinical trials

Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic of CC-95775 in Subjects With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma
Condition:   Lymphoma, Non-Hodgkin Intervention:   Drug: CC-95775 Sponsor:   Celgene Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 13, 2019 Category: Research Source Type: clinical trials

CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Non-Hodgkins Lymphoma
Conditions:   Lymphoma, Non-Hodgkin;   Diffuse Large B Cell Lymphoma;   Follicular Lymphoma Intervention:   Biological: CD19-targeted Chimeric Antigen Receptor (CAR) T Cells Sponsor:   Shanghai Ming Ju Biotechnology Co., Ltd. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 13, 2019 Category: Research Source Type: clinical trials

Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic of CC-95775 in Subjects With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma
Condition:   Lymphoma, Non-Hodgkin Intervention:   Drug: CC-95775 Sponsor:   Celgene Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 13, 2019 Category: Research Source Type: clinical trials

CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Non-Hodgkins Lymphoma
Conditions:   Lymphoma, Non-Hodgkin;   Diffuse Large B Cell Lymphoma;   Follicular Lymphoma Intervention:   Biological: CD19-targeted Chimeric Antigen Receptor (CAR) T Cells Sponsor:   Shanghai Ming Ju Biotechnology Co., Ltd. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 13, 2019 Category: Research Source Type: clinical trials

Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic of CC-95775 in Subjects With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma
Condition:   Lymphoma, Non-Hodgkin Intervention:   Drug: CC-95775 Sponsor:   Celgene Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 13, 2019 Category: Research Source Type: clinical trials

CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Non-Hodgkins Lymphoma
Conditions:   Lymphoma, Non-Hodgkin;   Diffuse Large B Cell Lymphoma;   Follicular Lymphoma Intervention:   Biological: CD19-targeted Chimeric Antigen Receptor (CAR) T Cells Sponsor:   Shanghai Ming Ju Biotechnology Co., Ltd. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 13, 2019 Category: Research Source Type: clinical trials

Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic of CC-95775 in Subjects With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma
Condition:   Lymphoma, Non-Hodgkin Intervention:   Drug: CC-95775 Sponsor:   Celgene Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 13, 2019 Category: Research Source Type: clinical trials

CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Non-Hodgkins Lymphoma
Conditions:   Lymphoma, Non-Hodgkin;   Diffuse Large B Cell Lymphoma;   Follicular Lymphoma Intervention:   Biological: CD19-targeted Chimeric Antigen Receptor (CAR) T Cells Sponsor:   Shanghai Ming Ju Biotechnology Co., Ltd. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 13, 2019 Category: Research Source Type: clinical trials

Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic of CC-95775 in Subjects With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma
Condition:   Lymphoma, Non-Hodgkin Intervention:   Drug: CC-95775 Sponsor:   Celgene Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 13, 2019 Category: Research Source Type: clinical trials

CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Non-Hodgkins Lymphoma
Conditions:   Lymphoma, Non-Hodgkin;   Diffuse Large B Cell Lymphoma;   Follicular Lymphoma Intervention:   Biological: CD19-targeted Chimeric Antigen Receptor (CAR) T Cells Sponsor:   Shanghai Ming Ju Biotechnology Co., Ltd. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 13, 2019 Category: Research Source Type: clinical trials

Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic of CC-95775 in Subjects With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma
Condition:   Lymphoma, Non-Hodgkin Intervention:   Drug: CC-95775 Sponsor:   Celgene Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 13, 2019 Category: Research Source Type: clinical trials

CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Non-Hodgkins Lymphoma
Conditions:   Lymphoma, Non-Hodgkin;   Diffuse Large B Cell Lymphoma;   Follicular Lymphoma Intervention:   Biological: CD19-targeted Chimeric Antigen Receptor (CAR) T Cells Sponsor:   Shanghai Ming Ju Biotechnology Co., Ltd. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 13, 2019 Category: Research Source Type: clinical trials

Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic of CC-95775 in Subjects With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma
Condition:   Lymphoma, Non-Hodgkin Intervention:   Drug: CC-95775 Sponsor:   Celgene Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 13, 2019 Category: Research Source Type: clinical trials

CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Non-Hodgkins Lymphoma
Conditions:   Lymphoma, Non-Hodgkin;   Diffuse Large B Cell Lymphoma;   Follicular Lymphoma Intervention:   Biological: CD19-targeted Chimeric Antigen Receptor (CAR) T Cells Sponsor:   Shanghai Ming Ju Biotechnology Co., Ltd. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 13, 2019 Category: Research Source Type: clinical trials

Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic of CC-95775 in Subjects With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma
Condition:   Lymphoma, Non-Hodgkin Intervention:   Drug: CC-95775 Sponsor:   Celgene Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 13, 2019 Category: Research Source Type: clinical trials

CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Non-Hodgkins Lymphoma
Conditions:   Lymphoma, Non-Hodgkin;   Diffuse Large B Cell Lymphoma;   Follicular Lymphoma Intervention:   Biological: CD19-targeted Chimeric Antigen Receptor (CAR) T Cells Sponsor:   Shanghai Ming Ju Biotechnology Co., Ltd. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 13, 2019 Category: Research Source Type: clinical trials

Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic of CC-95775 in Subjects With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma
Condition:   Lymphoma, Non-Hodgkin Intervention:   Drug: CC-95775 Sponsor:   Celgene Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 13, 2019 Category: Research Source Type: clinical trials

CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Non-Hodgkins Lymphoma
Conditions:   Lymphoma, Non-Hodgkin;   Diffuse Large B Cell Lymphoma;   Follicular Lymphoma Intervention:   Biological: CD19-targeted Chimeric Antigen Receptor (CAR) T Cells Sponsor:   Shanghai Ming Ju Biotechnology Co., Ltd. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 13, 2019 Category: Research Source Type: clinical trials

Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic of CC-95775 in Subjects With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma
Condition:   Lymphoma, Non-Hodgkin Intervention:   Drug: CC-95775 Sponsor:   Celgene Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 13, 2019 Category: Research Source Type: clinical trials

CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Non-Hodgkins Lymphoma
Conditions:   Lymphoma, Non-Hodgkin;   Diffuse Large B Cell Lymphoma;   Follicular Lymphoma Intervention:   Biological: CD19-targeted Chimeric Antigen Receptor (CAR) T Cells Sponsor:   Shanghai Ming Ju Biotechnology Co., Ltd. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 13, 2019 Category: Research Source Type: clinical trials

Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic of CC-95775 in Subjects With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma
Condition:   Lymphoma, Non-Hodgkin Intervention:   Drug: CC-95775 Sponsor:   Celgene Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 13, 2019 Category: Research Source Type: clinical trials

CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Non-Hodgkins Lymphoma
Conditions:   Lymphoma, Non-Hodgkin;   Diffuse Large B Cell Lymphoma;   Follicular Lymphoma Intervention:   Biological: CD19-targeted Chimeric Antigen Receptor (CAR) T Cells Sponsor:   Shanghai Ming Ju Biotechnology Co., Ltd. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 13, 2019 Category: Research Source Type: clinical trials

Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic of CC-95775 in Subjects With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma
Condition:   Lymphoma, Non-Hodgkin Intervention:   Drug: CC-95775 Sponsor:   Celgene Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 13, 2019 Category: Research Source Type: clinical trials

CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Non-Hodgkins Lymphoma
Conditions:   Lymphoma, Non-Hodgkin;   Diffuse Large B Cell Lymphoma;   Follicular Lymphoma Intervention:   Biological: CD19-targeted Chimeric Antigen Receptor (CAR) T Cells Sponsor:   Shanghai Ming Ju Biotechnology Co., Ltd. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 13, 2019 Category: Research Source Type: clinical trials

Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic of CC-95775 in Subjects With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma
Condition:   Lymphoma, Non-Hodgkin Intervention:   Drug: CC-95775 Sponsor:   Celgene Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 13, 2019 Category: Research Source Type: clinical trials

A Safety and Pharmacokinetic Study of IGM-2323 in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma
Conditions:   Non-Hodgkin Lymphoma;   Follicular Lymphoma;   DLBCL;   Mantle Cell Lymphoma;   Marginal Zone Lymphoma Intervention:   Drug: IGM-2323 Sponsor:   IGM Biosciences, Inc. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 10, 2019 Category: Research Source Type: clinical trials